<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2026-6808</article-id><article-id custom-type="edn" pub-id-type="custom">NTIYNE</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-6808</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОГНОЗИРОВАНИЕ И ДИАГНОСТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROGNOSIS AND DIAGNOSTICS</subject></subj-group></article-categories><title-group><article-title>Белок, связывающий жирные кислоты, как показатель прогноза у пациентов с острой сердечной недостаточностью</article-title><trans-title-group xml:lang="en"><trans-title>Fatty acid binding protein as a prognostic indicator in patients with acute heart failure</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3453-5914</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бычкова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bychkova</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ассистент кафедры пропедевтики внутренних болезней № 2 института клинической медицины.</p><p>ул. Островитянова, д. 1, Москва, 117997</p></bio><bio xml:lang="en"><p>assistant of the Department of Propaedeutics of Internal Diseases №2  of the Institute of Clinical Medicine.</p><p>Ostrovityanova str., 1, Moscow, 117997</p></bio><email xlink:type="simple">drunk-bee@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-7188-2260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Звягина</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Zvyagina</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Студент 4 курса.</p><p>Ул. Болдина, д. 128, Тула, 300028</p></bio><bio xml:lang="en"><p>Boldina str., 128, Tula, 300028</p></bio><email xlink:type="simple">lena_zvyagina@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7479-418X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Резник</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reznik</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., доцент, зав. кафедрой пропедевтики внутренних болезней № 2 института клинической медицины; врач-терапевт, кардиолог, врач функциональной диагностики, ультразвуковой диагностики.</p><p>Ул. Лобачевского, д. 42, Москва, 119415</p></bio><bio xml:lang="en"><p>Lobachevsky str., 42, Moscow, 119415</p></bio><email xlink:type="simple">elenaresnik@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО Тульский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tula State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России; ГБУЗ "ГКБ № 31 им. акад. Г.М. Савельевой ДЗМ"</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University; Savelyeva City Clinical Hospital № 31</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>07</day><month>07</month><year>2026</year></pub-date><volume>31</volume><issue>5</issue><fpage>6808</fpage><lpage>6808</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бычкова М.С., Звягина Е.О., Резник Е.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Бычкова М.С., Звягина Е.О., Резник Е.В.</copyright-holder><copyright-holder xml:lang="en">Bychkova M.S., Zvyagina E.O., Reznik E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/6808">https://russjcardiol.elpub.ru/jour/article/view/6808</self-uri><abstract><sec><title>Цель</title><p>Цель. Сравнить прогноз пациентов с острой сердечной недостаточностью (ОСН) при положительном и отрицательном результате определения сердечного белка, связывающего жирные кислоты (сБСЖК).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. У 63 человек, госпитализированных по поводу тяжелой ОСН III-IV класса по классификации Killip, проведено определение сБСЖК в первые 3 ч от начала симптоматики, качественным методом с помощью индивидуальных тест-систем. Наблюдение за пациентами проводилось в течение 12 [9; 13] мес.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с положительным результатом определения белка была более высокая летальность в стационаре и за все время наблюдения. Уровень тропонина I выше значений 99 перцентиля связан с более высокой летальностью в отдаленном периоде, а N-концевой промозговой натрийуретический пептид не взаимосвязан с риском летального исхода у пациентов с тяжелой ОСН.</p></sec><sec><title>Заключение</title><p>Заключение. сБСЖК можно рассматривать как прогностический маркер неблагоприятного исхода у пациентов с тяжелой ОСН.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To compare the prognosis of patients with acute heart failure (AHF) with positive and negative cardiac fatty acid binding protein (cFABP) tests.</p></sec><sec><title>Material and methods</title><p>Material and methods. In 63 patients hospitalized for severe Killip class III-IV AHF, cFABP was measured within the first 3 hours of symptom onset using a qualitative method with individual test kits. Patients were followed for 12 [9; 13] months. Results. Patients with a positive cFABP test had higher in-hospital and overall mortality. Troponin I levels above the 99th percentile are associated with higher long-term mortality, while N-terminal pro-brain natriuretic peptide is not associated with the death risk in patients with severe AHF.</p></sec><sec><title>Conclusion</title><p>Conclusion. cFABP can be considered a prognostic marker of adverse outcome in patients with severe AHF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>острая сердечная недостаточность</kwd><kwd>белок</kwd><kwd>связывающий жирные кислоты</kwd><kwd>прогноз</kwd><kwd>летальность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute heart failure</kwd><kwd>fatty acid binding protein</kwd><kwd>prognosis</kwd><kwd>mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Abubakar M, Irfan U, Abdelkhalek A, et al. Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review. J Cardiovasc Transl Res. 2024;17(6):1258-85. doi:10.1007/s12265-024-10540-8.</mixed-citation><mixed-citation xml:lang="en">Abubakar M, Irfan U, Abdelkhalek A, et al. Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review. J Cardiovasc Transl Res. 2024;17(6):1258-85. doi:10.1007/s12265-024-10540-8.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Netala VR, Hou T, Wang Y, et al. Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis. Int J Mol Sci. 2025;26(7):3218. doi:10.3390/ijms26073218.</mixed-citation><mixed-citation xml:lang="en">Netala VR, Hou T, Wang Y, et al. Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis. Int J Mol Sci. 2025;26(7):3218. doi:10.3390/ijms26073218.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pyati AK, Devaranavadagi BB, Sajjannar SL, et al. Heart–Type Fatty Acid–Binding Protein, in Early Detection of Acute Myocardial Infarction: Comparison with CK–MB, Troponin I and Myoglobin. Indian J Clin Biochem. 2016;31(4):439-45. doi:10.1007/s12291-015-0544-7.</mixed-citation><mixed-citation xml:lang="en">Pyati AK, Devaranavadagi BB, Sajjannar SL, et al. Heart–Type Fatty Acid–Binding Protein, in Early Detection of Acute Myocardial Infarction: Comparison with CK–MB, Troponin I and Myoglobin. Indian J Clin Biochem. 2016;31(4):439-45. doi:10.1007/s12291-015-0544-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kochmareva ЕА, Kokorin VА, Volkova АL, et al. Predictors of short term outcomes in high and moderate risk pulmonary thromboembolism. Russian Journal of Cardiology. 2017;(9):7-12. (In Russ.) Кочмарева Е. А., Кокорин В. А., Волкова А. Л. и др. Предикторы краткосрочных осложнений тромбоэмболии легочной артерии высокого и промежуточного риска. Российский кардиологический журнал. 2017;(9):7-12. doi:10.15829/1560-4071-2017-9-7-12.</mixed-citation><mixed-citation xml:lang="en">Kochmareva ЕА, Kokorin VА, Volkova АL, et al. Predictors of short term outcomes in high and moderate risk pulmonary thromboembolism. Russian Journal of Cardiology. 2017;(9):7-12. (In Russ.) doi:10.15829/1560-4071-2017-9-7-12.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kokorin VA, Gasanov М, Gordeev IG, et al. Qualitative test for the fatty acid binding cardiac protein in early diagnostics of myocardial infarction: subanalysis of Russian multi-center study ISPOLIN. Russian Journal of Cardiology. 2017;(11):62-7. (In Russ.) Кокорин В. А., Гасанов М. З., Гордеев И. Г. и др. Качественное определение белка, связывающего жирные кислоты в ранней дифференциальной диагностике инфаркта миокарда: субанализ Российского многоцентрового исследования ИСПОЛИН. Российский кардиологический журнал. 2017;(11):62-7. doi:10.15829/1560-4071-2017-11-62-67.</mixed-citation><mixed-citation xml:lang="en">Kokorin VA, Gasanov М, Gordeev IG, et al. Qualitative test for the fatty acid binding cardiac protein in early diagnostics of myocardial infarction: subanalysis of Russian multi-center study ISPOLIN. Russian Journal of Cardiology. 2017;(11):62-7. (In Russ.) doi:10.15829/1560-4071-2017-11-62-67.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kayani M, Fatima N, Yarra PC, et al. Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review. Cureus. 2024;16(2):e53445. doi:10.7759/cureus.53445.</mixed-citation><mixed-citation xml:lang="en">Kayani M, Fatima N, Yarra PC, et al. Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review. Cureus. 2024;16(2):e53445. doi:10.7759/cureus.53445.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Elzantout AS, Ahmed Mohamed A, Fouda MS, et al. Evaluation of diagnostic performances of Pro–neurotensin and Heart–type fatty acid binding protein. as reliable biomarkers for cardiovascular diseases. J Immunoassay Immunochem. 2025; 46(1):49-74. doi:10.1080/15321819.2024.2430332.</mixed-citation><mixed-citation xml:lang="en">Elzantout AS, Ahmed Mohamed A, Fouda MS, et al. Evaluation of diagnostic performances of Pro–neurotensin and Heart–type fatty acid binding protein. as reliable biomarkers for cardiovascular diseases. J Immunoassay Immunochem. 2025; 46(1):49-74. doi:10.1080/15321819.2024.2430332.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Goel H, Melot J, Krinock MD, et al. Heart–type fatty acid–binding protein: an overlooked cardiac biomarker. Ann Med. 2020;52(8):444-61. doi:10.1080/07853890.2020.1800075.</mixed-citation><mixed-citation xml:lang="en">Goel H, Melot J, Krinock MD, et al. Heart–type fatty acid–binding protein: an overlooked cardiac biomarker. Ann Med. 2020;52(8):444-61. doi:10.1080/07853890.2020.1800075.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Schoenenberger AW, Stallone F, Walz B, et al. Incremental value of heart-type fatty acidbinding protein in suspected acute myocardial infarction early after symptom onset. Eur Heart J Acute Cardiovasc Care. 2016;5(2):185-92. doi:10.1177/2048872615571256.</mixed-citation><mixed-citation xml:lang="en">Schoenenberger AW, Stallone F, Walz B, et al. Incremental value of heart-type fatty acidbinding protein in suspected acute myocardial infarction early after symptom onset. Eur Heart J Acute Cardiovasc Care. 2016;5(2):185-92. doi:10.1177/2048872615571256.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Otaki Y, Watanabe T, Kubota I. Heart–type fatty acid–binding protein in cardiovascular disease: A systemic review. Clin Chim Acta. 2017;474:44-53. doi:10.1016/j.cca.2017.09.007.</mixed-citation><mixed-citation xml:lang="en">Otaki Y, Watanabe T, Kubota I. Heart–type fatty acid–binding protein in cardiovascular disease: A systemic review. Clin Chim Acta. 2017;474:44-53. doi:10.1016/j.cca.2017.09.007.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pоurafkari L, Tajlil A, Nader ND. Biоmarkers in diagnоsing and treatment of acute heart failure. Biomark Med. 2019;13(14):1235-49. doi:10.2217/bmm-2019-0134.</mixed-citation><mixed-citation xml:lang="en">Pоurafkari L, Tajlil A, Nader ND. Biоmarkers in diagnоsing and treatment of acute heart failure. Biomark Med. 2019;13(14):1235-49. doi:10.2217/bmm-2019-0134.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ozturk TC, Unluer E, Denizbasi A, et al. Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room? J Res Med Sci. 2011;16(12):1564-71.</mixed-citation><mixed-citation xml:lang="en">Ozturk TC, Unluer E, Denizbasi A, et al. Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room? J Res Med Sci. 2011;16(12):1564-71.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng YR, Ye LF, Cen XJ, et al. Low NT-proBNP levels: An early sign for the diagnosis of ischemic heart failure. Int J Cardiol. 2017;228:666-671. doi: 10.1016/j.ijcard.2016.11.139</mixed-citation><mixed-citation xml:lang="en">Zheng YR, Ye LF, Cen XJ, et al. Low NT-proBNP levels: An early sign for the diagnosis of ischemic heart failure. Int J Cardiol. 2017;228:666-671. doi: 10.1016/j.ijcard.2016.11.139</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kazimierczyk E, Kazimierczyk R, Harasim-Symbor E, et al. Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients. Clin Chim Acta. 2018;487:48-53. doi:10.1016/j.cca.2018.09.004.</mixed-citation><mixed-citation xml:lang="en">Kazimierczyk E, Kazimierczyk R, Harasim-Symbor E, et al. Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients. Clin Chim Acta. 2018;487:48-53. doi:10.1016/j.cca.2018.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann U, Espeter F, Weiß C, et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure — diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovasc Disord. 2015;15:50. doi:10.1186/s12872-015-0026-0.</mixed-citation><mixed-citation xml:lang="en">Hoffmann U, Espeter F, Weiß C, et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure — diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovasc Disord. 2015;15:50. doi:10.1186/s12872-015-0026-0.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.</mixed-citation><mixed-citation xml:lang="en">Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
